Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

The Nasdaq OMX Group Inc., of New York, reported the semi-annual re-ranking of the Nasdaq Biotechnology Index, which will become effective prior to the market's open on May 20

Adaptive Biotechnologies, of Seattle, entered a collaboration with Bristol-Myers Squibb Co., of New York, for the discovery of immunological biomarkers in oncology

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported positive topline results from AUGMENT COPD, the second six-month pivotal Phase III trial evaluating the efficacy and safety of investigational fixed-dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair (Genuairn outside the U.S.) inhaler

Bristol-Myers Squibb Co., of New York, said the FDA approved a supplemental new drug application for the HIV-1 therapy Sustiva (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg

and Memorial Sloan-Kettering Cancer Center in New York entered a partnership in hematologic cancers

Tonix Pharmaceuticals Holdings Corp., of New York, said it effected a 1-for-20 reverse stock split, effective May 1, as a step toward its intention to list its common stock on Nasdaq

Inc., of Whitehouse Station, N.J., and Pfizer Inc., of New York, have entered a worldwide (except Japan) collaborative agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose co-transporter (SGLT2) inhibitor being evaluated for the treatment of Type II diabetes...Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, said it disputes the allegations made by the U.S. Attorney's Office for the Southern

Pfizer Inc., of New York, said the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for Xeljanz (tofacitnib citrate) for the treatment of adults with moderate to severe active rheumatoid arthritis

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair...plc, of Dublin, Ireland, said its board has determined that New York-based Royalty Pharma's offer to acquire the company for $11.25 or less per share substantially

plc, of Dublin, Ireland, said its board has determined that New York-based Royalty Pharma's offer to acquire the company for $11.25 or less per share substantially undervalues the company...Ohr Pharmaceutical Inc., of New York, raised about $5.05 million from institutional and accredited shareholders through the exercise of Series B warrants

Inc., of Whitehouse Station, N.J., entered into a nonexclusive deal with Bristol-Myers Squibb Co., of New York, to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus infection genotype 1

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

Bristol-Myers Squibb Co., of New York, will invest $250 million to expand its large-scale biologics manufacturing facility in Devens, Mass., introducing biologics development and clinical trial manufacturing capabilities and adding about 350 employees

Pfizer Inc., of New York, said its palbociclib (PD-0332991), an oral and selective inhibitor of cyclin-dependent kinases 4 and 6, received breakthrough therapy designation by the FDA for the potential treatment of patients with breast cancer

Stemline Therapeutics Inc., of New York, said an ongoing collaboration with the Dana-Farber Cancer Institute featuring SL-401, currently in late-stage testing for hematological malignancies such as blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia, has shown activity in an additional hematologic malignancy, multiple myeloma, in preclinical models

Vertex Pharmaceuticals Inc., of Cambridge, Mass., agreed with Bristol-Myers Squibb Co., of New York, to carry out Phase II studies of hepatitis C virus treatment regimens that contain Vertex's nucleotide analogue polymerase inhibitor VX-135